Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Market Cap
$13.86M
EBITDA Margin
-988.11%
TTM Avg
-1002.20%
3Y Avg
-1043.90%
5Y Avg
-1194.77%
Market Cap
$14.05M
EBITDA Margin
-23.39%
TTM Avg
-215.41%
3Y Avg
-426.39%
5Y Avg
-612.06%
Market Cap
$13.30M
EBITDA Margin
-839.37%
TTM Avg
-1027.77%
3Y Avg
-3215.79%
5Y Avg
-3215.79%
Market Cap
$14.46M
EBITDA Margin
-855.47%
TTM Avg
-475.86%
3Y Avg
-335.10%
5Y Avg
-307.83%
Market Cap
$12.78M
EBITDA Margin
-5650.91%
TTM Avg
-5650.91%
3Y Avg
-12817.85%
5Y Avg
-12817.85%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Obsidian Therapeutics Inc. (OBX) | $13.75M | N/A | N/A | N/A | N/A |
| Sintx Technologies, Inc. (SINT)vs › | $13.86M | -988.11% | -1002.20% | -1043.90% | -1194.77% |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $14.05M | -23.39% | -215.41% | -426.39% | -612.06% |
| IN8bio, Inc. (INAB)vs › | $13.33M | N/A | N/A | N/A | N/A |
| Optimi Health Corp. (OPTH)vs › | $13.30M | -839.37% | -1027.77% | -3215.79% | -3215.79% |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.20M | N/A | N/A | N/A | N/A |
| Passage Bio, Inc. (PASG)vs › | $13.11M | N/A | N/A | N/A | N/A |
| Vyome Holdings, Inc. (HIND)vs › | $14.46M | -855.47% | -475.86% | -335.10% | -307.83% |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $12.78M | -5650.91% | -5650.91% | -12817.85% | -12817.85% |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $14.73M | -61.90% | -71.95% | -80.60% | -87.82% |
Gross Margin
N/A
EBITDA Margin
N/A
Operating Margin
N/A
Net Margin
N/A
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
